Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS)

Shu-Peng Zou(Tongji Hospital), Minghui Sun(Nanjing University of Information Science and Technology), Mengling Ouyang(Tongji Hospital), Qian Cheng(Tongji Hospital), Hai-Yun Yang(Lanzhou University), Xuan Shi(Tongji Hospital)
Expert Opinion on Drug Safety
August 23, 2023
Cited by 16


Related Papers